PolyPeptide Group AG (XSWX:PPGN) Total Operating Expense: CHF54.1 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:PPGN PolyPeptide Group AG XSWX:PPGN
73 GF Score
Price CHF45.70
GF Value CHF31.08
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is PolyPeptide Group AG Total Operating Expense?

PolyPeptide Group AG XSWX:PPGN -0.65% 73 Total Operating Expense is CHF54.1 Mil as of Dec. 2025. GuruFocus rates XSWX:PPGN with a GF Score™ of 73/100 and a GF Value™ of CHF31.08 (Significantly Overvalued). The stock has 9 warning signs investors should review.

PolyPeptide Group AG's Total Operating Expense for the six months ended in Dec. 2025 was CHF27.8 Mil. PolyPeptide Group AG's Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was CHF54.1 Mil.

PolyPeptide Group AG Total Operating Expense Related Terms

PolyPeptide Group AG Total Operating Expense Historical Data

* Premium members only.

The historical data trend for PolyPeptide Group AG's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PolyPeptide Group AG Total Operating Expense Chart

PolyPeptide Group AG Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial 41.10 41.15 40.48 42.26 53.98

PolyPeptide Group AG Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.00 22.24 20.68 26.28 27.84
XSWX:PPGN
73GF Score
PolyPeptide Group AG XSWX:PPGN
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PolyPeptide Group AG Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF54.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of CHF54.1 Mil mean?
PolyPeptide Group AG (XSWX:PPGN) has a Total Operating Expense of CHF54.1 Mil as of Dec. 2025. Total operating expense is the primary recurring expense associated with central operations. View historical data on PolyPeptide Group AG and its competitors.
Is PolyPeptide Group AG's Total Operating Expense too high?
PolyPeptide Group AG's current Total Operating Expense is CHF54.1 Mil. Overall, PolyPeptide Group AG has a GF Score™ of 73/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PolyPeptide Group AG's Total Operating Expense compare to ZTS and UTHR?
PolyPeptide Group AG's Total Operating Expense of CHF54.1 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Drug Manufacturers company?
A good Total Operating Expense depends on the Drug Manufacturers industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on PolyPeptide Group AG and its competitors. PolyPeptide Group AG's current Total Operating Expense is CHF54.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PolyPeptide Group AG stock overvalued right now?
Based on GuruFocus' analysis, PolyPeptide Group AG (XSWX:PPGN) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF31.08, compared to a current price of CHF45.70 — trading 47% above its estimated fair value. The current Total Operating Expense is CHF54.1 Mil. PolyPeptide Group AG's overall GF Score™ is 73/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For PolyPeptide Group AG (XSWX:PPGN), the current Total Operating Expense is CHF54.1 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PolyPeptide Group AG (XSWX:PPGN) Overvalued in 2026?

Based on GuruFocus' analysis, PolyPeptide Group AG stock appears to be overvalued. The current stock price of CHF45.70 is trading 47% above its estimated GF Value™ of CHF31.08. GuruFocus considers PolyPeptide Group AG to be Significantly Overvalued.

Key valuation signals for XSWX:PPGN:

  • Total Operating Expense: CHF54.1 Mil
  • GF Value™: CHF31.08 vs. price of CHF45.70 (47% above fair value)
  • GF Score™: 73/100 with 9 warning signs

No single metric tells the full story. See the XSWX:PPGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PolyPeptide Group AG Business Description

Address Neuhofstrasse 24, Baar, Zug, CHE, 6340
PolyPeptide Group AG is an independent contract development and manufacturing organization (CDMO) focused on peptides and oligonucleotides employed as an active pharmaceutical ingredients (APIs) and used as intermediates in therapeutic products. The company derives majority of its revenue from Europe and Asia.
73GF Score

Get the complete analysis for XSWX:PPGN

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF45.70
Price
CHF31.08
GF Value